Fragile X Syndrome Clinical Presentation

  • Author: Jennifer A Jewell, MD, MS; Chief Editor: Bruce Buehler, MD   more...
 
Updated: Aug 4, 2011
 

History

Significant family, developmental, cognitive, and neuropsychological histories are keys to diagnosis. Unusual musculoskeletal anomalies, feeding difficulties, and recurrent nonspecific medical problems are infrequently reported.

Family history

Screening and diagnosis in utero or during infancy is usually the result of a family history that features multiple male relatives with mental retardation.

Other clues to the diagnosis include a mother with learning disabilities, mental retardation, or both or family members with ataxia and tremors.

Female infertility secondary to premature ovarian failure and increased rates of dizygotic twinning have recently been discovered to be more common in fragile X carriers and may provide another clue to the diagnosis.

Developmental history

During infancy, developmental milestones are achieved as expected or are slightly delayed.

However, after the first year of life, delays in speech and language are notable, and fine motor skills are impaired.

As the patient matures, perseveration and echolalia may dominate speech patterns. Expressive language ability, short-term memory, and attempts at problem solving are significantly impaired.

Cognitive history

Intelligence quotient (IQ) frequently indicates mild-to-severe mental retardation (20-70). Females and less-affected males may have IQs that approach 80.

IQ may be higher in childhood than in adulthood because of slowing mental development and difficulties with IQ test taking rather than loss of intellect.

IQ in patients with premutations can be normal or slightly decreased.

Neuropsychological history

Patients have many neuropsychological features, including depression, general and separation anxiety, and oppositional defiant disorder.

Autisticlike behavior (especially poor eye contact and hand biting or hand flapping) is present in 16-30% of patients with fragile X syndrome. However, even patients with autisticlike behavior may have social conversation abilities. Molecular investigation for fragile X syndrome is the single laboratory test proven to aid in definitively diagnosing infantile autism.

Near-universal behavioral features of males with fragile X syndrome are similar to those observed in patients with attention deficit hyperactivity disorder (ADHD), including aggressive tendencies and attention deficits.

Approximately 20% of male patients and 5% of female patients have a seizure disorder, with nearly one half of those having persistent seizures that require anticonvulsant therapy. The onset of seizures is typically at age 6-24 months. The seizure type most often diagnosed is complex partial seizure. Additionally, simple febrile partial seizures and generalized tonic-clonic seizures may be present.

Many children have difficulty when routines are altered.

Some people with fragile X syndrome display features of obsessive-compulsive disorder, sensory integration disorder, or both. Others display self-injureous behavior and significant tantrums.

Musculoskeletal features

Features include pes planus, pectus excavatum, joint laxity, scoliosis, and joint dislocation.

Feeding difficulties

Affected individuals may manifest symptoms of reflux, vomiting, or both and, rarely, failure to gain weight during infancy and childhood. A minority of patients with fragile X syndrome demonstrate a Prader-Willi phenotype, which includes obesity due to severe hyperphagia.

Toileting difficulties

Patients typically have delayed toilet training and frequent enuresis after toilet training.

Recurrent nonspecific medical problems

Patients may have recurrent sinusitis, otitis media, and decreased visual acuity.

During the history taking, ask about apnea.[7]

Next

Physical

The phenotype of fragile X syndrome is difficult to diagnose in prepubertal children. Most physical examination findings are notable only after onset of puberty.

Growth

Childhood growth is marked by an early growth spurt. However, adult height is often average or slightly below average.

A study by Lachiewicz et al reported 3 statistically significant phenotypic characteristics of young males with fragile X syndrome compared with young males with other developmental delays.[8] These characteristics included the presence of a hallucal crease (a single crease between the first and second toes), sensitivity to touch, and the inability to touch the tongue to the lips.

A small subset of male patients were reported with obesity, poor linear growth, small hands and feet, and diffuse hyperpimentation.

Craniofacial

Adolescent and adult patients have a long, thin face with prominent ears, facial asymmetry, a head circumference higher than the 50th percentile, and a prominent forehead and jaw.

Mouth

The mouth has dental overcrowding and a high-arched palate.

Ears

Ears are typically large and may protrude.

Eyes

Strabismus is frequently noted. Ocassionally, nystagmus, astigmatism, and ptosis are present.

Extremities

Hands and feet manifest nonspecific findings, including hyperextensible finger joints, hand calluses, double-jointed thumbs, a single palmar crease, and pes planus. Clubfeet may be present at birth.

Back and chest

Pectus excavatum and scoliosis are frequent findings.

Genitals

Macroorchidism is nearly universal in adult males. In unaffected males, average testicular volume is 17 mL; in patients with fragile X syndrome, testicular volume is more than 25 mL and can be as high as 120 mL. During childhood, an increased incidence of inguinal hernias is reported.

Cardiac

A heart murmur or click consistent with mitral valve prolapse is often auscultated and requires consultation with a cardiologist.

Previous
Next

Causes

The genetic defect is dynamic and lies at the distal end of the long arm of the X chromosome. Careful examination of the karyotype of affected individuals' lymphocytes, cultured in a folate-depleted and thymidine-depleted medium, reveals a constriction followed by a thin strand of genetic material that extends beyond the long arm at the highly conserved band Xq27.3. This constriction and thin strand produce the appearance of a fragile portion of the X chromosome, leading to the term fragile X.

  • The function of the band Xq27.3, which is also termed the fragile X mental retardation-1 (FMR1) gene, is to synthesize fragile X mental retardation protein (FMRP), a regulatory protein that binds messenger RNA (mRNA) in neurons and dendrites.[9] In patients with a full mutation in the FMR1 gene, FMRP is not manufactured because of hypermethylation of FMR1, and brain development is impaired primarily because of abnormal synapse connections. Additionally, mutations in the FMR1 gene lead to excessive activity of the metabotropic glutamate receptor 5 (mGluR5), which results in many fragile X syndrome symptoms. FMRP is present in other tissues; however, its role is less understood.
  • Once identified and sequenced, the gene was discovered to contain a repeating base pair triplet (CGG) expansion, which is responsible for fragile X syndrome.
  • Unaffected individuals have 5-54 CGG repeats in the first exon at the 5' end of band Xq27.3. A span of 55-200 repeats is known as a premutation, whereas more than 200 repeats is a full mutation. Full mutation results in hypermethylation of the cysteine bases and restricts protein binding, leading to gene inactivation. Mosaic patterns are common. The number of repeats is unstable from generation to generation, making the pattern of inheritance difficult to predict. In addition, the degree of methylation is directly proportional to the signs and symptoms of fragile X syndrome.
  • Males with a full mutation have fragile X syndrome. Mothers of nearly all males with fragile X syndrome have premutation or fragile X syndrome. Males with fragile X syndrome pass a premutation to their daughters because sperm cells are mosaics. Sons are unaffected because they receive the Y chromosome from their fathers.
  • Half of females with the full mutation on a single X chromosome are unaffected because of inactivation of the other X chromosome. The other half of females have fragile X syndrome, although with less severe mental retardation than males with the disorder. These affected females can pass the gene to their children.
  • Males with a premutation are usually unaffected to mildly affected and transmit the premutation to their daughters. The mutation is stable; thus, the CGG triplets are not increased. Sons of affected males are unaffected because they receive the Y chromosome from their fathers.
  • Females with a premutation are usually unaffected to mildly affected. Unlike their male counterparts, the CGG triplets are unstable and increase in size during oogenesis. If the number of repeats exceeds 200 and the oocyte is fertilized, a male child will have fragile X syndrome, and a female child will have a 50% chance of having fragile X syndrome. The number of repeats is directly proportional to the risk of the disorder in an offspring.
  • Although most patients with fragile X syndrome have a CGG triplet expansion, few patients have a point mutation in the FMR1 gene or a deletion of the gene.[10]
Previous
 
 
Contributor Information and Disclosures
Author

Jennifer A Jewell, MD, MS  Assistant Professor, Department of Pediatrics, University of Vermont School of Medicine; Pediatric Hospitalist, The Barbara Bush Children's Hospital at Maine Medical Center

Jennifer A Jewell, MD, MS is a member of the following medical societies: American Academy of Pediatrics, Massachusetts Medical Society, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael Fasullo, PhD  Senior Scientist, Ordway Research Institute; Associate Professor, State University of New York at Albany; Adjunct Associate Professor, Center for Immunology and Microbial Disease, Albany Medical College

Michael Fasullo, PhD is a member of the following medical societies: American Society for Biochemistry and Molecular Biology, Environmental Mutagen Society, Genetics Society of America, and Radiation Research Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David Flannery, MD, FAAP, FACMG  Vice Chair of Education, Chief, Section of Medical Genetics, Professor, Department of Pediatrics, Medical College of Georgia

David Flannery, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics and American College of Medical Genetics

Disclosure: Nothing to disclose.

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Bruce Buehler, MD  Professor, Department of Pediatrics and Genetics, Director RSA, University of Nebraska Medical Center

Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association

Disclosure: Nothing to disclose.

References
  1. Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychi. 1943;6:154-7.

  2. Lubs HA. A marker X chromosome. Am J Hum Genet. May 1969;21(3):231-44. [Medline]. [Full Text].

  3. Murphy MM. A review of mathematical learning disabilities in children with fragile X syndrome. Dev Disabil Res Rev. 2009;15(1):21-7. [Medline].

  4. De Smedt B, Swillen A, Verschaffel L, Ghesquiere P. Mathematical learning disabilities in children with 22q11.2 deletion syndrome: a review. Dev Disabil Res Rev. 2009;15(1):4-10. [Medline].

  5. Spath MA, Feuth TB, Smits AP, Yntema HG, Braat DD, Thomas CM. Predictors and risk model development for menopausal age in fragile X premutation carriers. Genet Med. Jul 2011;13(7):643-50. [Medline].

  6. Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey. Pediatrics. Aug 2009;124(2):527-33. [Medline].

  7. de Vries BB, Halley DJ, Oostra BA, Niermeijer MF. The fragile X syndrome. J Med Genet. Jul 1998;35(7):579-89. [Medline].

  8. Lachiewicz AM, Dawson DV, Spiridigliozzi GA. Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males. Am J Med Genet. Jun 5 2000;92(4):229-36. [Medline].

  9. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. Jan 2009;123(1):378-90. [Medline].

  10. Oostra BA, Willemsen R. FMR1: a gene with three faces. Biochim Biophys Acta. Feb 19 2009;[Medline].

  11. Health supervision for children with fragile x syndrome. Pediatrics. May 2011;127(5):994-1006. [Medline].

  12. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion. No. 338: Screening for fragile X syndrome. Obstet Gynecol. Jun 2006;107(6):1483-5. [Medline].

  13. Biancalana V, Toft M, Le Ber I, et al. FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. Arch Neurol. Jun 2005;62(6):962-6. [Medline].

  14. Brown WT. Perspectives and molecular diagnosis of the fragile X syndrome. Clin Lab Med. Dec 1995;15(4):859-75. [Medline].

  15. Brown WT. The fragile X: progress toward solving the puzzle. Am J Hum Genet. Aug 1990;47(2):175-80. [Medline].

  16. Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am. Jul 1990;72(6):889-96. [Medline].

  17. Dyer-Friedman J, Glaser B, Hessl D, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. J Am Acad Child Adolesc Psychiatry. Mar 2002;41(3):237-44. [Medline].

  18. Finucane B. Should all pregnant women be offered carrier testing for fragile X syndrome?. Clin Obstet Gynecol. Dec 1996;39(4):772-82. [Medline].

  19. Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet. Jun 2008;16(6):666-72. [Medline].

  20. Gleicher N, Weghofer A, Barad DH. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril. Apr 1 2008;[Medline].

  21. Goldson E, Hagerman RJ. The fragile X syndrome. Dev Med Child Neurol. Sep 1992;34(9):826-32. [Medline].

  22. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. May 2004;74(5):805-16. [Medline].

  23. Hagerman RJ, Ono MY, Hagerman PJ. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry. Sep 2005;18(5):490-6. [Medline].

  24. Hall SS, Lightbody AA, Huffman LC, Lazzeroni LC, Reiss AL. Physiological correlates of social avoidance behavior in children and adolescents with fragile x syndrome. J Am Acad Child Adolesc Psychiatry. Mar 2009;48(3):320-9. [Medline].

  25. Handa V, Goldwater D, Stiles D, et al. Long CGG-repeat tracts are toxic to human cells: implications for carriers of Fragile X premutation alleles. FEBS Lett. May 9 2005;579(12):2702-8. [Medline].

  26. Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. Sep 1 2006;140(17):1804-13. [Medline].

  27. Hessl D, Dyer-Friedman J, Glaser B, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile x syndrome. Pediatrics. Nov 2001;108(5):88. [Medline].

  28. Kenneson A, Warren ST. The female and the fragile X reviewed. Semin Reprod Med. Jun 2001;19(2):159-65. [Medline].

  29. Kosinovsky B, Hermon S, Yoran-Hegesh R, et al. The yield of laboratory investigations in children with infantile autism. J Neural Transm. Apr 2005;112(4):587-96. [Medline].

  30. Laxova R. Fragile X syndrome. Adv Pediatr. 1994;41:305-42. [Medline].

  31. Loesch DZ, Churchyard A, Brotchie P, Marot M, Tassone F. Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet. May 2005;67(5):412-7. [Medline].

  32. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns. Aug 2005;14(4):249-70. [Medline].

  33. Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome: information needs for health planners. J Med Screen. 1997;4(2):60-94. [Medline].

  34. Neri G, Opitz JM. Sixty years of X-linked mental retardation: a historical footnote. Am J Med Genet. Fall 2000;97(3):228-33. [Medline].

  35. Oostra BA, Halley DJ. Complex behavior of simple repeats: the fragile X syndrome. Pediatr Res. Nov 1995;38(5):629-37. [Medline].

  36. Reiss AL, Freund L. Fragile X syndrome. Biol Psychiatry. Jan 15 1990;27(2):223-40. [Medline].

  37. Simensen RJ, Rogers RC. Fragile-X syndrome. Am Fam Physician. May 1989;39(5):185-93. [Medline].

  38. Sotos JF. Genetic disorders associated with overgrowth. Clin Pediatr (Phila). Jan 1997;36(1):39-49. [Medline].

  39. Sutherland GR, Mulley JC. Fragile X syndrome and fragile XE mental retardation. Prenat Diagn. Dec 1996;16(13):1199-211. [Medline].

  40. Tarleton JC, Saul RA. Molecular genetic advances in fragile X syndrome. J Pediatr. Feb 1993;122(2):169-85. [Medline].

  41. Terracciano A, Chiurazzi P, Neri G. Fragile X syndrome. Am J Med Genet C Semin Med Genet. Jul 11 2005;[Medline].

  42. Turk J. The fragile-X syndrome. On the way to a behavioural phenotype. Br J Psychiatry. Jan 1992;160:24-35. [Medline].

  43. Visootsak J, Warren ST, Anido A, Graham JM Jr. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila). Jun 2005;44(5):371-81. [Medline].

  44. Warren ST, Nelson DL. Advances in molecular analysis of fragile X syndrome [see comments]. JAMA. Feb 16 1994;271(7):536-42. [Medline].

  45. Wattendorf DJ, Muenke M. Diagnosis and management of fragile X syndrome. Am Fam Physician. Jul 1 2005;72(1):111-3. [Medline].

  46. Weinhausel A, Haas OA. Evaluation of the fragile X (FRAXA) syndrome with methylation-sensitive PCR. Hum Genet. Jun 2001;108(6):450-8. [Medline].

  47. Zhou Y, Lum JM, Yeo GH, Kiing J, Tay SK, Chong SS. Simplified molecular diagnosis of fragile X syndrome by fluorescent methylation-specific PCR and GeneScan analysis. Clin Chem. Aug 2006;52(8):1492-500. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.